WO2003095613A3 - Acides nucleiques, polypeptides, et methodes permettant de moduler l'apoptose - Google Patents

Acides nucleiques, polypeptides, et methodes permettant de moduler l'apoptose Download PDF

Info

Publication number
WO2003095613A3
WO2003095613A3 PCT/US2003/014049 US0314049W WO03095613A3 WO 2003095613 A3 WO2003095613 A3 WO 2003095613A3 US 0314049 W US0314049 W US 0314049W WO 03095613 A3 WO03095613 A3 WO 03095613A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
apoptosis
polypeptides
nucleic acids
dhs
Prior art date
Application number
PCT/US2003/014049
Other languages
English (en)
Other versions
WO2003095613A2 (fr
Inventor
Catherine Taylor
Tzann-Wei Wang
Larry Petrov
John C Carlson
Richard Narayansingh
John E Thompson
Dominic Cliche
Marianne Kaup
Original Assignee
Senesco Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/141,647 external-priority patent/US7166467B2/en
Priority to EP03728710A priority Critical patent/EP1509251B1/fr
Priority to AU2003234482A priority patent/AU2003234482C1/en
Priority to NZ536958A priority patent/NZ536958A/en
Priority to CA002484144A priority patent/CA2484144A1/fr
Priority to KR10-2004-7017741A priority patent/KR20050007383A/ko
Application filed by Senesco Technologies Inc filed Critical Senesco Technologies Inc
Priority to JP2004503607A priority patent/JP4754819B2/ja
Priority to DE60319369T priority patent/DE60319369D1/de
Publication of WO2003095613A2 publication Critical patent/WO2003095613A2/fr
Publication of WO2003095613A3 publication Critical patent/WO2003095613A3/fr
Priority to IL16500704A priority patent/IL165007A0/xx
Priority to HK06109240.3A priority patent/HK1088824A1/xx
Priority to IL198348A priority patent/IL198348A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)

Abstract

L'invention concerne des acides nucléiques isolés et/ou purifiés de déoxyhypusine synthase (DHS) et de facteur-5A (eIF-5A) d'initiation eucaryote spécifique de l'apoptose chez le rat, et des polypeptides. L'invention concerne également des méthodes permettant de moduler une apoptose à l'aide de DHS et du facteur eIF-5A spécifique d'une apoptose, des oligonucléotides antisens et des vecteurs d'expression de DHS et du facteur eIF-5A spécifique d'une apoptose utilisés dans lesdites méthodes.
PCT/US2003/014049 2002-05-07 2003-05-07 Acides nucleiques, polypeptides, et methodes permettant de moduler l'apoptose WO2003095613A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE60319369T DE60319369D1 (de) 2002-05-07 2003-05-07 Nukleinsäuren, polypeptide und verfahren zur modulierung von apoptosis
AU2003234482A AU2003234482C1 (en) 2002-05-07 2003-05-07 Nucleic acids, polypeptides, and methods for modulating apoptosis
NZ536958A NZ536958A (en) 2002-05-07 2003-05-07 Nucleic acids, polypeptides, and methods for modulating apoptosis
CA002484144A CA2484144A1 (fr) 2002-05-07 2003-05-07 Acides nucleiques, polypeptides, et methodes permettant de moduler l'apoptose
KR10-2004-7017741A KR20050007383A (ko) 2002-05-07 2003-05-07 핵산, 폴리펩타이드 및 아폽토시스 조절방법
EP03728710A EP1509251B1 (fr) 2002-05-07 2003-05-07 Acides nucleiques, polypeptides, et methodes permettant de moduler l'apoptose
JP2004503607A JP4754819B2 (ja) 2002-05-07 2003-05-07 アポトーシス調節に関する核酸、ポリペプチド及び方法
IL16500704A IL165007A0 (en) 2002-05-07 2004-11-03 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
HK06109240.3A HK1088824A1 (en) 2002-05-07 2006-08-21 Nucleic acids, polypeptides, and methods for modulating apoptosis
IL198348A IL198348A0 (en) 2002-05-07 2009-04-23 Mucleic acids, polypeptides, compositions, and methods for modulating apoptosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/141,647 2002-05-07
US10/141,647 US7166467B2 (en) 2001-07-23 2002-05-07 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
US10/200,148 US7968523B2 (en) 2001-07-23 2002-07-23 Method for inducing apoptosis using apoptosis-specific EIF5-A
US10/200,148 2002-07-23

Publications (2)

Publication Number Publication Date
WO2003095613A2 WO2003095613A2 (fr) 2003-11-20
WO2003095613A3 true WO2003095613A3 (fr) 2004-10-28

Family

ID=29423041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/014049 WO2003095613A2 (fr) 2002-05-07 2003-05-07 Acides nucleiques, polypeptides, et methodes permettant de moduler l'apoptose

Country Status (10)

Country Link
US (3) US7968523B2 (fr)
EP (1) EP1509251B1 (fr)
KR (1) KR20050007383A (fr)
AT (1) ATE387220T1 (fr)
AU (1) AU2003234482C1 (fr)
CA (1) CA2484144A1 (fr)
DE (1) DE60319369D1 (fr)
IL (1) IL165007A0 (fr)
NZ (1) NZ536958A (fr)
WO (1) WO2003095613A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381708B2 (en) 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
US7968523B2 (en) * 2001-07-23 2011-06-28 Senesco Technologies, Inc. Method for inducing apoptosis using apoptosis-specific EIF5-A
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
US7595308B2 (en) * 2002-11-18 2009-09-29 Grenpharma Llc Compositions for treating and/or preventing diseases characterized by the presence of metal ions
NZ542665A (en) * 2003-03-05 2008-05-30 Senesco Technologies Inc Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
EP1636364A2 (fr) * 2003-06-06 2006-03-22 Senesco Technologies, Inc. Inhibition d'eif-5a specifique de l'apoptose ("eif-5a1") au moyen d'oligonucleotides antisens et de petits arn interferents utilises comme agents therapeutiques anti-inflammatoires
WO2005009445A1 (fr) * 2003-07-22 2005-02-03 Cv Therapeutics, Inc. Antagonistes du recepteur de l'adenosine a1
US20140371299A1 (en) * 2004-06-07 2014-12-18 Senesco Technologies, Inc. Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis
TW200615001A (en) * 2004-07-20 2006-05-16 Senesco Technologies Inc Use of apoptosis-specific eIF-5A siRNAs and antisense polynucleotides to inhibit/suppress an inflammatory response
WO2006047477A1 (fr) * 2004-10-22 2006-05-04 Grenpharama Llc Compositions destinees a traiter et / ou prevenir des maladies caracterisees par la presence d'ions metalliques
NZ556236A (en) * 2004-12-03 2009-12-24 Senesco Technologies Inc Apoptosis-specific eIF-5A and polynucleotides encoding same
EP2019142A3 (fr) * 2004-12-03 2009-04-01 Senesco Technologies, Inc. Isoformes de elF-5A et leurs procédés d'utilisation
JP2009519351A (ja) * 2005-12-13 2009-05-14 セネスコ テクノロジーズ，インコーポレイティド 多発性骨髄腫細胞を死滅させるためのｅＩＦ−５Ａの使用
CN101605893A (zh) * 2006-03-20 2009-12-16 森尼斯科技术公司 在供体收获过程期间保护胰岛细胞使之免于凋亡的新方法
CN102124108A (zh) * 2007-08-20 2011-07-13 森尼斯科技术公司 Eif-5a1 sirna保护胰岛细胞免受凋亡和维持它们功能性的用途
WO2009144933A1 (fr) 2008-05-27 2009-12-03 国立大学法人東京大学 Inducteur de l'apoptose

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168064A (en) 1990-04-20 1992-12-01 The Regents Of The University Of California Endo-1,4-β-glucanase gene and its use in plants
US5344846A (en) 1992-12-30 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells
WO1996000286A1 (fr) * 1994-06-27 1996-01-04 Toagosei Co., Ltd. Compose d'acide nucleique antisens
CN1173897A (zh) 1995-02-13 1998-02-18 诺瓦蒂斯有限公司 真核起始因子5A(eIF－5A)突变体
US6020139A (en) 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5849587A (en) 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US6214572B1 (en) 1996-08-09 2001-04-10 The General Hospital Corporation Programmed cell death and ICH-3
US6124091A (en) 1997-05-30 2000-09-26 Research Corporation Technologies, Inc. Cell growth-controlling oligonucleotides
WO1999001551A2 (fr) 1997-06-30 1999-01-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouvel inhibiteur de proliferation cellulaire
US6538182B1 (en) 1999-07-06 2003-03-25 Senesco, Inc. DNA encoding a plant deoxyhypusine synthase, a plant eukaryotic initiation factor 5A, transgenic plants and a method for controlling senescence programmed and cell death in plants
EP1200468A1 (fr) 1999-08-06 2002-05-02 PHARMACIA & UPJOHN COMPANY Cristallisation et determination de structure du facteur p d'elongation du staphylococcus aureus
ES2182635B1 (es) * 2000-05-25 2004-06-16 Ramon Soler Fornt Valvula distribuidora de agua para grifos de baño y ducha.
US7166467B2 (en) 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
US7968523B2 (en) * 2001-07-23 2011-06-28 Senesco Technologies, Inc. Method for inducing apoptosis using apoptosis-specific EIF5-A

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARAGLIA ET AL: "The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells", JOURNAL OF BIOCHEMISTRY, vol. 133, no. 6, June 2003 (2003-06-01), pages 757 - 765, XP002978955 *
CARAGLIA ET AL: "The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis", AMINO ACIDS, vol. 20, no. 2, 2001, pages 91 - 104, XP002978938 *
WANG ET AL: "Isolation and characterization of senescence-induced cDNAs encoding deoxyhypusine synthase and eucaryotic translation initiation factor 5A from tomato", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 20, 18 May 2001 (2001-05-18), pages 17541 - 17549, XP002227361 *
WOLFF ET AL: "Deoxyhypusine synthase from rat testis: Purification and characterization", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 15, 14 April 1995 (1995-04-14), pages 8660 - 8666, XP002978937 *

Also Published As

Publication number Publication date
ATE387220T1 (de) 2008-03-15
AU2003234482C1 (en) 2010-02-18
EP1509251B1 (fr) 2008-02-27
AU2003234482A1 (en) 2003-11-11
WO2003095613A2 (fr) 2003-11-20
IL165007A0 (en) 2005-12-18
US20030050272A1 (en) 2003-03-13
CA2484144A1 (fr) 2003-11-20
NZ536958A (en) 2005-12-23
US20110288156A1 (en) 2011-11-24
AU2003234482B2 (en) 2008-07-31
DE60319369D1 (de) 2008-04-10
EP1509251A2 (fr) 2005-03-02
US7968523B2 (en) 2011-06-28
KR20050007383A (ko) 2005-01-17
EP1509251A4 (fr) 2005-08-10
US20140212969A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
WO2003095613A3 (fr) Acides nucleiques, polypeptides, et methodes permettant de moduler l'apoptose
WO2003010286A3 (fr) Acides nucleiques, polypeptides et methodes permettant de moduler une apoptose
AU2002365811A1 (en) Methods for the selection and cloning of nucleic acid molecules free of unwanted nucleotide sequence alterations
WO2004035170A3 (fr) Composition permettant de separer des molecules
AU2001294060A1 (en) Chimeric cytoplasmic signalling molecules derived from cd137
WO2005047511A3 (fr) Expression bacterienne d'inhibiteurs de protease et variants de ceux-ci
AU2002318386A1 (en) Methods for characterization of nucleic acid molecules
WO2003093441A3 (fr) Procede de regulation de l'expression genique
WO2001023412A3 (fr) Procedes de criblage d'agents inhibiteurs de l'agregation des polypeptides
WO2002040668A3 (fr) Proteines et sequences d'adn sous-jacentes a ces proteines, utilisees pour traiter les inflammations
WO2004007664A3 (fr) Vecteurs d'acides nucleiques
WO2002099080A3 (fr) Methodes de clonage d'adn, a faible pourcentage de clones negatifs, a l'aide d'oligonucleotides longs
WO2005000888A3 (fr) Nouveaux promoteurs de l'actine beta et de la rps21, et leurs utilisations
DK1675956T3 (da) Minimal DNA-sekvens, der virksom som chromatinisolator, og dennes anvendelse til proteinekspression
WO2002010393A3 (fr) Molecules d'acide nucleique isolees codant pour des facteurs inductibles derives de lymphocytes t, ou interleukines-21, proteines codees et leur utilisation
WO1998044104A3 (fr) Flip-gene et flip-proteine
WO2006060823A3 (fr) Eif-5a spécifique de l'apoptose et polynucléotides codant pour un tel facteur
WO2003057843A3 (fr) Procedes et materiaux de modulation de trpc4
WO2001066752A3 (fr) Genes specifiques de la reproduction
WO2003100020A3 (fr) Procedes et constructions destines a l'expression a haut rendement de la clostripaine
WO2001040521A3 (fr) Acides nucleiques contenant des polymorphismes mononucleotidiques et procedes d'utilisation correspondants
WO2003057847A8 (fr) Procedes et substances de modulation de l'enac-beta
WO2003004678A3 (fr) Nouveaux recepteurs
WO2004050674A3 (fr) Procedes et materiaux de modulation des trpm2
WO2002070699A3 (fr) Nouveaux cofacteurs du recepteur alpha des oestrogenes et procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 165007

Country of ref document: IL

Ref document number: 2484144

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047017741

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004503607

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003234482

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 536958

Country of ref document: NZ

Ref document number: 3824/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003728710

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038161540

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020047017741

Country of ref document: KR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003728710

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 536958

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 536958

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2003728710

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 198348

Country of ref document: IL